The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | IsaVCd and IsaR maintenance in newly diagnosed myeloma with severe renal impairment
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the EAE116 study (NCT05147493) evaluating isatuximab, bortezomib and cyclophosphamide (IsaVCd) and isatuximab plus lenalidomide (IsaR) maintenance in patients with newly diagnosed multiple myeloma with severe renal impairment. He highlights the regimen’s efficacy and tolerability, alongside the importance of prompt supportive care and early anti-myeloma treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We know that about a third of patients with multiple myeloma present with impaired renal function and several of these patients have severe renal dysfunction. So we developed a regimen which included isatuximab with bortezomib and cyclophosphamide that could be given to patients with severe renal function. This regimen was relatively well tolerated. It was effective. And as far as myeloma response is concerned, and also we had a significant number of patients that had improvement of their renal impairment...
We know that about a third of patients with multiple myeloma present with impaired renal function and several of these patients have severe renal dysfunction. So we developed a regimen which included isatuximab with bortezomib and cyclophosphamide that could be given to patients with severe renal function. This regimen was relatively well tolerated. It was effective. And as far as myeloma response is concerned, and also we had a significant number of patients that had improvement of their renal impairment. So this data indicate that this quadruple combination is effective in patients with myeloma who need treatment and who present with renal impairment. These patients represent an emergency. They should receive appropriate supportive measures, hydration, treatment of hypercalcemia, avoidance of nephrotoxic drugs, and they should be started as soon as possible to an effective treatment for myeloma. We usually start with dexamethasone and then we add these other agents that are active, they can induce responses and they are well tolerated because they don’t have renal excretion.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
